Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura - PubMed (original) (raw)
Clinical Trial
. 2001 Aug 15;98(4):952-7.
doi: 10.1182/blood.v98.4.952.
Affiliations
- PMID: 11493438
- DOI: 10.1182/blood.v98.4.952
Free article
Clinical Trial
Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura
R Stasi et al. Blood. 2001.
Free article
Abstract
The role of rituximab, a chimeric monoclonal antibody directed against the CD20 antigen, in the treatment of patients with chronic idiopathic thrombocytopenic purpura (ITP) has not been determined. The effectiveness and side effects of this therapeutic modality were investigated in a cohort of 25 individuals with chronic ITP. All patients had ITP that had been resistant to between 2 and 5 different therapeutic regimens, including 8 patients who had already failed splenectomy. Patients were scheduled to receive intravenous rituximab at the dose of 375 mg/m(2) once weekly for 4 weeks. Rituximab infusion-related side effects were observed in 18 patients, but were of modest intensity and did not require discontinuation of treatment. A complete response (platelet count greater than 100 x 10(9)/L) was observed in 5 cases, a partial response (platelet count between 50 and 100 x 10(9)/L) in 5 cases, and a minor response (platelet count below 50 x 10(9)/L, with no need for continued treatment) in 3 cases, with an overall response rate of 52%. In 7 cases, responses were sustained (6 months or longer). In 2 patients with relapsed disease, repeat challenge with rituximab induced a new response. In patients with a complete or partial response, a significant rise in platelet concentrations was observed early during the course of treatment, usually 1 week after the first rituximab infusion. No clinical or laboratory parameter was found to predict treatment outcome, although there was a suggestion that women and younger patients have a better chance of response. In conclusion, rituximab therapy has a limited but valuable effect in patients with chronic ITP. In view of its mild toxicity and the lack of effective alternative treatments, its use in the setting of chronic refractory ITP is warranted. (Blood. 2001;98:952-957)
Comment in
- Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura.
Stasi R, Stipa E, Forte V, Meo P, Amadori S. Stasi R, et al. Blood. 2002 May 15;99(10):3872-3. doi: 10.1182/blood-2002-02-0392. Blood. 2002. PMID: 12014370 No abstract available.
Similar articles
- Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC. Braendstrup P, et al. Am J Hematol. 2005 Apr;78(4):275-80. doi: 10.1002/ajh.20276. Am J Hematol. 2005. PMID: 15795920 - [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura].
Wang W, Yu QH, Zhang HY, Chu XX, Chen F, Zhang CQ, Zhou YH, Hou M. Wang W, et al. Zhonghua Nei Ke Za Zhi. 2008 Mar;47(3):225-7. Zhonghua Nei Ke Za Zhi. 2008. PMID: 18785508 Clinical Trial. Chinese. - The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.
Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB. Cooper N, et al. Br J Haematol. 2004 Apr;125(2):232-9. doi: 10.1111/j.1365-2141.2004.04889.x. Br J Haematol. 2004. PMID: 15059147 - Monoclonal antibodies in the treatment of immune thrombocytopenic purpura (ITP).
Gómez-Almaguer D. Gómez-Almaguer D. Hematology. 2012 Apr;17 Suppl 1:S25-7. doi: 10.1179/102453312X13336169155213. Hematology. 2012. PMID: 22507772 Review. - Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.
Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG. Arnold DM, et al. Ann Intern Med. 2007 Jan 2;146(1):25-33. doi: 10.7326/0003-4819-146-1-200701020-00006. Ann Intern Med. 2007. PMID: 17200219 Review.
Cited by
- Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice.
Červinek L, Černá O, Čaniga M, Konířová E, Hluší A, Šimkovič M, Pospíšil Z, Čermák J, Kozák T, Mayer J, Doubek M. Červinek L, et al. Int J Hematol. 2012 Nov;96(5):594-9. doi: 10.1007/s12185-012-1206-7. Epub 2012 Oct 26. Int J Hematol. 2012. PMID: 23099924 Clinical Trial. - Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia: Long-Term Follow-Up of 15 Cases.
Hindilerden F, Yönal-Hindilerden İ, Yenerel MN, Nalçacı M, Diz-Küçükkaya R. Hindilerden F, et al. Turk J Haematol. 2017 Mar 1;34(1):72-80. doi: 10.4274/tjh.2016.0086. Epub 2016 Apr 22. Turk J Haematol. 2017. PMID: 27102929 Free PMC article. - Successful treatment with the monoclonal antibody rituximab in two children with refractory autoimmune thrombocytopenia.
Pusiol A, Cesaro S, Nocerino A, Picco G, Zanesco L, Bisogno G. Pusiol A, et al. Eur J Pediatr. 2004 Jun;163(6):305-7. doi: 10.1007/s00431-004-1417-x. Eur J Pediatr. 2004. PMID: 15346911 - Monoclonal antibodies in the treatment of chronic lymphocytic leukemia.
Liu NS, O'Brien S. Liu NS, et al. Med Oncol. 2004;21(4):297-304. doi: 10.1385/MO:21:4:297. Med Oncol. 2004. PMID: 15579912 Review. - Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS).
Rao VK, Price S, Perkins K, Aldridge P, Tretler J, Davis J, Dale JK, Gill F, Hartman KR, Stork LC, Gnarra DJ, Krishnamurti L, Newburger PE, Puck J, Fleisher T. Rao VK, et al. Pediatr Blood Cancer. 2009 Jul;52(7):847-52. doi: 10.1002/pbc.21965. Pediatr Blood Cancer. 2009. PMID: 19214977 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources